Perrigo
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 5.1b | 4.1b | 4.5b | 4.7b | 4.5b | 4.7b | 4.9b |
% growth | 5 % | (18 %) | 8 % | 5 % | (4 %) | 5 % | 3 % |
EBITDA | 1.3b | 886m | 511m | 654m | 693m | 787m | 838m |
% EBITDA margin | 26 % | 21 % | 11 % | 14 % | 15 % | 17 % | 17 % |
Profit | (163m) | (68.9m) | (141m) | (12.7m) | (166m) | 92.7m | 184m |
% profit margin | (3 %) | (2 %) | (3 %) | - | (4 %) | 2 % | 4 % |
EV / revenue | 1.8x | 1.7x | 1.8x | 1.6x | 1.6x | 1.5x | 1.4x |
EV / EBITDA | 6.8x | 7.7x | 15.8x | 11.8x | 10.5x | 9.0x | 8.2x |
R&D budget | 178m | 122m | 123m | 123m | - | - | - |
R&D % of revenue | 4 % | 3 % | 3 % | 3 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | - | ||
$600m | Post IPO Equity | ||
* | N/A | N/A | Post IPO Debt |
Total Funding | - |
Related Content
Recent News about Perrigo
EditPerrigo Company plc is a leading global provider of high-quality, affordable self-care products. Operating in the consumer healthcare market, Perrigo serves a diverse range of clients including retail chains, pharmacies, and direct consumers. The company’s business model focuses on manufacturing and distributing over-the-counter (OTC) healthcare products, infant formulas, and nutritional products. Perrigo generates revenue through the sale of these products under both its own brand and private labels for retailers. The company leverages its extensive manufacturing capabilities and commitment to quality to maintain competitive pricing while ensuring product efficacy and safety. Additionally, Perrigo is dedicated to community well-being through its charitable foundation, which supports educational programs, healthcare access, and disaster relief efforts.
Keywords: self-care, OTC healthcare, infant formulas, nutritional products, private labels, retail chains, pharmacies, manufacturing, quality, community well-being.